Sign In
Buy LLY
$1,185.71
-6.23 (-0.523%)
At Close: Aug 07, 2026
Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It
10:31am, Friday, 01'st Dec 2023
Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.
1 Underrated Reason to Buy Eli Lilly Stock
09:45am, Friday, 01'st Dec 2023
The shares have vaulted as a result of its recently approved weight-loss drug. But it also pays a dividend, which has increased steadily over the years.
US obesity docs expect Lilly weight-loss drug to show similar heart benefit as Wegovy
08:29am, Friday, 01'st Dec 2023
Some leading U.S. obesity specialists say they expect Eli Lilly's powerful weight-loss drug Zepbound will produce the same or similar heart benefits as Novo Nordisk's popular Wegovy as they belong to
Verve Therapeutics: Lilly's Experience A Welcome Addition To In Vivo Gene Therapy Program
01:19pm, Thursday, 30'th Nov 2023
Verve Therapeutics is focused on developing in vivo gene editing therapies for cardiovascular disease. The company aims to disrupt the chronic care model for CVD by targeting genes related to atherosc
Eli Lilly's Weight-Management Drug Outperformed Ozempic. Is It Time to Buy?
05:26am, Thursday, 30'th Nov 2023
A large analysis of electronic health records shows a strong advantage for Eli Lilly's weight management treatment tirzepatide. Patients given tirzepatide were more than twice as likely to achieve a 1
4 Large Drug Stocks to Watch as IBD Market Gains Traction
11:20am, Wednesday, 29'th Nov 2023
As demand for novel IBD treatments rises, investment in this dynamic sector could be rewarding. Some of the key players in the market are AbbVie (ABBV), J&J (JNJ), Lilly (LLY) and Pfizer (PFE).
How to earn $500 a month from this stock?
07:32am, Wednesday, 29'th Nov 2023
Pfizer's (NASDAQ: PFE) stock continued its 11-month decline in November after its third-quarter sales missed expectations amid waning demand for Covid products.
Arecor extends its relationship with Lilly as it inks another technology deal
02:27am, Wednesday, 29'th Nov 2023
Arecor Therapeutics PLC (AIM:AREC) announces an expanded collaboration with Eli Lilly and Company that will see the former's Arestat technology use to develop a new enhanced liquid formulation of an
Eli Lilly and Company (LLY) Presents at 6th Evercore ISI HealthCONx Conference (Transcript)
08:25pm, Tuesday, 28'th Nov 2023
Eli Lilly and Company (NYSE:LLY ) 6th Evercore ISI HealthCONx Conference November 28, 2023 3:50 PM ET Company Participants Dan Skovronsky - EVP, Chief Scientific and Medical Officer Conference Call Pa
3 Large Drug Stocks That Have Outperformed Industry YTD
10:31am, Tuesday, 28'th Nov 2023
Eli Lilly (LLY), Novo Nordisk (NVO) and Novartis (NVS) have outperformed the industry this year.
Lilly's Mounjaro leads to more and faster weight loss than Novo obesity drug, data analysis finds
06:41pm, Monday, 27'th Nov 2023
Overweight or obese adults lost more weight and shed pounds faster using Eli Lilly's Mounjaro than those taking Novo Nordisk's popular rival weight loss drug, according to an analysis of health record
Study finds Mounjaro outperforms Ozempic in overweight & obese adults: Truveta's VP of Research
06:27pm, Monday, 27'th Nov 2023
Dr. Nick Stucky, VP of Research at Truveta, joins 'Fast Money' to talk the results of a study comparing weight-loss drugs Mounjaro and Ozempic.
Mounjaro outperforms Ozempic for weight loss in adults, study says
01:36pm, Monday, 27'th Nov 2023
Eli Lilly and Co (NYSE:LLY)'s diabetes drug Mounjaro is more effective for weight loss than Novo Nordisk (NYSE:NVO)'s Ozempic in overweight or obese adults, a real-world analysis by Truveta Research r
Mounjaro is more effective for weight loss than Ozempic: study reveals
12:22pm, Monday, 27'th Nov 2023
Mounjaro – a popular treatment for diabetes is more effective for losing weight than Ozempic, as per a large study of real-word data by Truveta Research.
Investing $10K in S&P 500 buys this much of largest stocks
08:51am, Monday, 27'th Nov 2023
For years now, a significant cohort of investors gravitated towards the allure of the S&P 500 index over individual stocks.
